Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-180-0 | CAS number: 7440-74-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- not applicable
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: Crj: CD(SD) IGS rats (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan, Inc
- Age at study initiation: 5 wk
- Weight at study initiation: 125-145 g (male) and 116-130g (female)
- Fasting period before study: 18h
- Diet (ad libitum): pellet diet (MF, Oriental Yeast co, Ltd)
- Water (ad libitum): tap water irradiated by UV rays after passing through a 5µm filter
- Acclimation period: 6days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.2 ± 2
- Humidity (%): 55 ± 15
- Air changes (per hr): 12 changes per hour
- Photoperiod (hrs dark / hrs light): 12 hrs dark/12 hrs light - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: the dosing volume was set at 10mg/kg and the dose volume for individual animals was calculated based on the body weight measured just before dosing
DOSAGE PREPARATION (if unusual): done on the administration day - Doses:
- 2000mg/kg
- No. of animals per sex per dose:
- 12
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: body weights of all animals were measured before dosing and on days 4, 8, and 15 (day of administration was designated as day 1)
- Necropsy of survivors performed: no
- Other examinations performed:
clinical signs: observed 5 times (shortly before dosing, and 0.5, 1, 3 and 5h after dosing) on the those day and thereafter once a day for 14 days
body weight: measured before dosing and on days 4, 8, and 15 - Statistics:
- Barlett's test: to test the homogeneity of the variances of the data
one way analysis of variance: used when to variances of the treatment group and the control group were homogenous; to analyze statistical significances in the numerical data (body weight, food consumption, hematology, blood chemistry, and organ weights)
Kruskal-Wallis test: used when to variances of the treatment group and the control group were heterogenous; to analyze statistical significances in the numerical data (body weight, food consumption, hematology, blood chemistry, and organ weights)
Dunnett's test or Dunnett-type ranksum test: to examine statistical significances in the data between groups
chi square test: to examine statistical significances in graded categorical data (urinalysis) - Preliminary study:
- a preliminary study was done in which no death were observed
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality observed
- Clinical signs:
- other: No abnormalities in clinical signs observed
- Gross pathology:
- Necroscopy:
no abnormalities observed - Other findings:
- spontaneous changes: in one male of the 2000 mg/kg group pelvic dilatation of the kidneys was observed
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Tests done according to standard protocol. Good quality and considered useful for setting the reference value for acute oral toxicity (LD50>2000mg/kg)
Although this study represented an out of date test guideline as it was deleted on 17th December 2002 and replaced with the fixed dose (TG 420 [4]) and acute toxic class (OECD TG 425 [5]) methods, it meets in light of current test guidelines (i.e. TG 420) the minimum animal required of 5 animals (Asakura et al. used 12)
The preference within the current test guideline is that test substances are preferentially administered as an aqueous solution/suspension/emulsion followed in order of preference by a solution/suspension/emulsion in oil (e.g. corn oil) as used by Asakura et al). - Executive summary:
A limit study with Crj:CD (SD) IGS rats (SPF) was carried out according to OECD guideline no 401 to assess the oral LD50. No deaths and no abnormalities in clinical signs, body weights, and necropsy findings were observed for any of the animals. An LD50 value >2000mg/kg bw was reported.
none
Data source
Reference
- Reference Type:
- publication
- Title:
- Oral toxicity of indium in rats: single and 28-day repeated administration studies.
- Author:
- Asakura K, Satoh H, Chiba M, Okamoto M, Serizawa K, Nakano M and Omae K
- Year:
- 2 008
- Bibliographic source:
- J Occup Health. 50(6):471-9
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Indium
- EC Number:
- 231-180-0
- EC Name:
- Indium
- Cas Number:
- 7440-74-6
- Molecular formula:
- In
- IUPAC Name:
- indium
- Details on test material:
- - Name of test material (as cited in study report): Indium
- Analytical purity: 99%
- Lot/batch No.: 67246G
- Stability under test conditions: stable based on the characteristics of indium
- Storage condition of test material: room temperature
- Other: particle diameter : M45 µm pass
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan, Inc
- Age at study initiation: 5 wk
- Weight at study initiation: 125-145 g (male) and 116-130g (female)
- Fasting period before study: 18h
- Diet (ad libitum): pellet diet (MF, Oriental Yeast co, Ltd)
- Water (ad libitum): tap water irradiated by UV rays after passing through a 5µm filter
- Acclimation period: 7days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.2 ± 2
- Humidity (%): 55 ± 15
- Air changes (per hr): 12 changes per hour
- Photoperiod (hrs dark / hrs light): 12 hrs dark/12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: the dosing volume was set at 10mg/kg and the dose volume for individual animals was calculated based on the body weight measured just before dosing
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- MAXIMUM DOSE VOLUME APPLIED: the dosing volume was set at 10mg/kg and the dose volume for individual animals was calculated based on the body weight measured just before dosing
- Duration of treatment / exposure:
- 28 days and a 14 day recovery period after completion of the dosing period
- Frequency of treatment:
- once daily in the morning throughout the 28-day dosing period
Doses / concentrationsopen allclose all
- Dose / conc.:
- 40 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 1000 mg/kg : 12 F + 12 M
200 mg/kg: 6F + 6M
40mg/kg: 6F+ 6M
0 mg/kg: 12F + 12M - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Prior tho the 28 day repeated oral dose toxicity study, a preliminary dose finding "A fourteen-day repeated oral toxicity preliminary study in rats" with dose levels : 0, 100, 500 and 1000 mg/kg was conducted. No changes attributable to the test substance were observed in clinical signs, body weights, hematology or organ weights (brain, thymus, liver, kidney, adrenal glands, spleen, testis and ovary) on necropsy. As such, the highest dose level was set at 1000mg/kg and the middle and the lower dose levels at 200 and 40 mg/kg respectively
- Rationale for animal assignment (if not random): animals were assigned to groups by the stratified-by-weight randomization method so that they were evenly assigned with respect to the mean body weight.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice a day ( before and after administration) throughout the dosing period and once day in the morning during the recovery period
BODY WEIGHT: Yes
- Time schedule for examinations: once a week
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on the days of the sheduled necropsy after the completion of dosing and recovery periods (days 29 and 43)
- Anaesthetic used for blood collection: Yes : ip injection of thiopental sodium
- Animals fasted: No data
- How many animals: 12 M and 12 F
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on the days of the sheduled necropsy after the completion of dosing and recovery periods (days 29 and 43)
- Animals fasted: No data
- How many animals:12 M and 12 F
URINALYSIS: Yes
- Time schedule for collection of urine: collected on day 27
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- HISTOPATHOLOGY: Yes : on the heart, liver , spleen, kidneys, and adrenals obtained from animals of the control and 1000 mg/kg groups and on gross lesions of any group
- Other examinations:
- none
- Statistics:
- Barlett's test: to test the homogeneity of the variances of the data
one way analysis of variance: used when to variances of the treatment group and the control group were homogenous; to analyze statistical significances in the numerical data (body weight, food consumption, hematology, blood chemistry, and organ weights)
Kruskal-Wallis test: used when to variances of the treatment group and the control group were heterogenous; to analyze statistical significances in the numerical data (body weight, food consumption, hematology, blood chemistry, and organ weights)
Dunnett's test or Dunnett-type ranksum test: to examine statistical significances in the data between groups
chi square test: to examine statistical significances in graded categorical data (urinalysis)
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No abnormal clinical signs observed in any animal during the dosing and recovery periods
BODY WEIGHT AND WEIGHT GAIN: No significant body weight difference between the control group and any treatment group
HAEMATOLOGY: no significant hematological change attributable to indium after the dosing period. After the recovery period, a significantly higher value of the ratio of lymphocyte and a significantly lower value of the ratio of monocyte were observed in females of the 1000mg/kg group, as compared with the control group
CLINICAL CHEMISTRY no significant differences in blood chemistry between the control group and any treatment group after the indium-dosing group. After the recovery period, a significantly lower value of total chlolesterol was observed in females of the 1000mg/kg group
URINALYSIS: During the dosing period, a significantly higher value of urobilinogen was observed in females of the 1000mg/kg group, as compared to with the control group
ORGAN WEIGHTS: significantly lower values of absolute kidney weights in female rats of the 200mg/kg group after the dosing period.
HISTOPATHOLOGY: NON-NEOPLASTIC:
spontaneous changes in histopathological findings were observed in animals of the 1000mg/kg groups after the dosing period: focal myocardial degeneration/fibrosis in the heart, periportal inflammaroty cells and microgranuloma in the liver, basophilic renal tubule , renal cysts, hyaline droplets of proximal tubular epithelium and focal inflammatory cell infiltration in the kidneys and an increase in lipid droplets of the fascicular zone in the adrenals. Most of the changes were also observed in the control group as well as in the 1000 mg/kg group
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw (total dose)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- haematology
- histopathology: non-neoplastic
- mortality
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
The authors discuss that haematological and blood chemistry changes may not be related to indium because they were not observed at the end of the dosing period and both total white blood cell count and overall nutritional condition were stable. Also they considered the significantly higher value of urobilinogen observed in females of the 1000 mg/kg group during the dosing period as not necessarily related to indium because neither liver dysfunction nor anemia coincided with it. The authors state that experiments using more animals might demonstrate the irrelevancy of indium to changes of parameters more clearly.
Concerning pathology, the significantly lower values of absolute kidney weights in female rats of the 200mg/kg group after the dosing period, was considered as a spontaneous change because it occurred without dose-dependency and relative kidney weights were not significantly different between treated groups and the control group.
The hispathological changes observed in several rats were also considered as changes that were unrelated to indium because they were slight, nonspecific and not dose dependent.
Applicant's summary and conclusion
- Conclusions:
- Under the test conditions, NOAEL of the test material in rats was determined to be 1000 mg/kg for males and females
- Executive summary:
This study was conducted to evaluate the subchronic toxicity (28 days) of the test material in rats Crj:CD(SD) IGS rats (SPF).
The study followed was similar to OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity in Rodents).
Rats of both sexes received by oral gavage the test material at 0, 20, 400 and 1000 mg/kg for 28 days. No changes related to indium with regard to clinical signs, body weights, food consumption, hematology, blood chemistry, urinalysis, organ weights, necropsy or histopathological findings were reported.
Under these test conditions, NOAEL of the test material in rats was determined to be 1000 mg/kg for males and females
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.